INTERNATIONAL PATENT: GILGAMESH PHARMACEUTICALS, INC. FILES APPLICATION FOR "A TREATMENT FOR PATIENTS WITH MOOD DISORDERS USING N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)- N-METHYLETHAN-1-AMINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF"

GENEVA, June 4 -- GILGAMESH PHARMACEUTICALS, INC. (113 University Place, Suite 1019New York, New York 10023) filed a patent application (PCT/US2024/057185) for "A TREATMENT FOR PATIENTS WITH MOOD DISORDERS USING N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)- N-METHYLETHAN-1-AMINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF" on Nov 22, 2024. With publication no. WO/2025/111597, the details related to the patent application was published on May 30, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): KRUEGEL, Andrew Carry (c/o Gilgamesh Pharmaceuticals, Inc.113 University Place, Suite 1019New York, New York...